Sonnet Biotherapeutics Holdings Inc

NASDAQ:SONNUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company’s technology, namely fully human albumin binding (FHAB) helps to develop biologic medicines. FHAB utilizes a fully human single chain antibody fragment linked to either one or two therapeutic molecules capable of affecting single or bispecific mechanisms of action. The FHAB construct contains a domain, which is designed to bind to and hitch hike on human serum albumin for transport to targets, such as solid tumors or to the lymphatic system. It designed the construct to improve drug accumulation in specific tissues, as well as to extend the duration of activity in the body. FHAB development candidates are produced in a mammalian cell culture, which enables glycosylation, thereby reducing the risk of immunogenicity. FHAB technology can help in drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory and hematological conditions.

Contact Information

Headquarters

100 Overlook Center, Suite 102PRINCETON, NJ, United States 08540

Phone

609-375-2227

Fax

302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer

Pankaj Mohan

Chief Financial Officer

John Cross

Chief Scientific Officer

John Cini

Chief Technical Officer

Susan Dexter

Chief Medical Officer

Richard Kenney